Cancer Centers Support Grants (CCSGs) is sponsored by National Cancer Institute (NCI). The Cancer Center Support Grant (CCSG) provides resources and infrastructure to facilitate the coordination of interdisciplinary programs across a broad spectrum of cancer research, from basic laboratory research to clinical investigation to population science.

PAR-25-444: Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) Department of Health and Human Services Part 1.

Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations National Cancer Institute ( NCI ) Funding Opportunity Title Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional) Check for any recent Notices of NIH Policy Changes that may impact application requirements.

Funding Opportunity Number (FON) Companion Notice of Funding Opportunity See Section III. 3. Additional Information on Eligibility .

Assistance Listing Number(s) Notice of Funding Opportunity Purpose This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers.

CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas; and 3) Basic Cancer Centers, which focus on basic laboratory research.

The purpose of all types of NCI-Designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries.

Cancer Centers supported through this NOFO are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

Funding Opportunity Goal(s) The goal of this NOFO is to provide an organizational focus and stimulus for the highest quality cancer research that effectively promotes interdisciplinary cancer research aimed toward the ultimate goal of reducing cancer incidence, mortality and morbidity.

The Cancer Center Support Grant (CCSG) provides the resources and infrastructure to facilitate the coordination of interdisciplinary programs across a broad spectrum of research from basic laboratory research to clinical investigation to population science.

The CCSG supports salaries for scientific leadership of the Center, shared resources for funded center investigators, certain administrative costs, planning and evaluation, and developmental funds for new recruitments and feasibility studies. Open Date (Earliest Submission Date) The following table includes NIH standard due dates marked with an asterisk.

Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Required Application Instructions It is critical that applicants follow the Multi-Project (M) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from the NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced.

Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide , follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants. gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

Use the NIH ASSIST system to prepare, submit and track your application online. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants. gov and eRA Commons to track your application.

Check with your institutional officials regarding availability. Part 1. Overview Information Part 2.

Full Text of Announcement Section I. Notice of Funding Opportunity Description Section II. Award Information Section III.

Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI.

Award Administration Information Section VII. Agency Contacts Section VIII. Other Information Part 2.

Full Text of Announcement Section I. Notice of Funding Opportunity Description This Notice of Funding Opportunity (NOFO) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-Designated Cancer Centers. NCI-Designated Cancer Centers serve as major sources of discovery into the nature of cancer and of the development of more effective approaches to prevention, diagnosis, and therapy.

They contribute significantly to the development of Shared Resources that support cancer relevant research, and they collaborate and coordinate their research efforts with other NCI-funded programs and investigators.

The objectives of the NCI Cancer Centers Program are to foster highly interactive cancer research through support of the following: Formal, interactive scientific Research Programs comprised of investigators with common scientific interests and goals, yielding competitively funded research grants and contracts and productive collaborations; Centralized Shared Resources that provide access to technologies, services, and scientific consultation that enhance scientific interaction and productivity; Developmental Funding that allows the Center to pursue newly identified priorities, strengthen weaker scientific areas, and explore new collaborations; Activities that engage the populations within the catchment area in the conducted research and other Center activities; Efforts to coordinate and enhance existing cancer research education, training, and career development activities; Centralized Cancer Center Administration for resources and services, fiscal management and other supportive activities; and Centralized scientific oversight of cancer clinical trials.

NCI support to Cancer Centers is intended to foster excellence in research across a broad spectrum of scientific and medical concerns relevant to cancer. To facilitate discovery and its translation into direct benefit to patients and the general public, the NCI awards CCSGs to institutions that have a critical mass of cancer-relevant scientific research.

The CCSG focus on research derives from the belief that a culture of discovery, scientific excellence, transdisciplinary research, and collaboration yields tangible benefits extending far beyond the generation of new knowledge. The National Cancer Act officially established the Cancer Centers Program in 1971.

The legislation was based on the report of a congressional committee, which concluded that a formalized Cancer Centers Program would provide a unity of purpose, a centralized platform for sharing concepts and resources, and a management structure necessary to achieve progress toward the goal of preventing and curing cancer.

The Act grandfathered in twelve existing Centers that were already receiving support through a variety of NCI grants and contracts and authorized the establishment of additional Centers. It also implemented a standard funding mechanism (the P30 Cancer Center Support Grant or CCSG) and guidelines, and created an administrative and organizational home for the Program at the NCI.

Based on this early legislation, qualified applicant institutions receive the CCSG award and accompanying NCI designation for successfully meeting a spectrum of rigorous competitive standards associated with scientific and organizational merit. While CCSG requirements have evolved over the years, the grant continues to support research infrastructure that enhances collaborative, transdisciplinary research productivity.

CCSG grants provide funding for formalized cancer Research Programs, Shared Resources, scientific and administrative management, planning and evaluation activities, development of new scientific opportunities, community outreach and engagement, coordination of cancer training and education, and centralized clinical trial oversight and functions.

Although the CCSG does not directly fund the wider range of activities at Cancer Centers, an NCI-Designated Cancer Center links state-of-the-art research and care, thus perpetuating the translational continuum.

To decrease cancer incidence and mortality among populations within its catchment area, including underserved populations, it also establishes partnerships with other health delivery systems and state and community agencies for dissemination of evidence-based findings.

Over the past several decades, the number of NCI-Designated Cancer Centers has grown extensively; today they are in a variety of organizational settings across the United States. An NCI-Designated Cancer Center is a local, regional, and national resource, directly serving its community and, through the knowledge it creates, the nation as a whole.

The NCI recognizes three types of Cancer Centers: Basic Cancer Centers have scientific agendas primarily focused on basic laboratory research. While not all basic findings require a translational endpoint, basic cancer centers conduct pre-clinical translation and develop linkages with other institutions that will foster application of laboratory findings for public benefit where appropriate.

Clinical Cancer Centers have scientific agendas focused on basic laboratory; clinical; and prevention, cancer control, and population-based science. All areas of science are linked collaboratively.

Comprehensive Cancer Centers demonstrate reasonable depth and breadth of cancer research activities in each of three major areas: basic laboratory; clinical; and prevention, control, population-based science, as demonstrated in the formal Research Programs.

Comprehensive Cancer Centers also have substantial transdisciplinary research that bridges these scientific areas, which is evaluated in the Research Programs and as part of the Six Essential Characteristics (i.e. Transdisciplinary Collaboration and Coordination; see below).

They are effective in serving their catchment area, as well as the broader population, through the cancer research they support and the cancer control activities they undertake, as demonstrated in Community Outreach and Engagement.

They integrate cancer training and education of biomedical researchers and community health care professionals into programmatic efforts to enhance the scientific mission and potential of the Center, as demonstrated by the Cancer Research Training and Education Coordination component.

Comprehensive Centers are expected to be strong in all four areas indicated above; strengths in some areas cannot mitigate weaknesses in one or more other areas. NOTE: Clinical and Comprehensive Cancer Centers serve a specific catchment area , and in addition to cancer research of broad applicability, they conduct research of particular relevance to their catchment area.

A Center’s catchment area is the self-defined geographic area that the Center serves or intends to serve in the research it conducts, the communities it engages, and the outreach it performs. It must include the area from which the Center draws the majority of its patients, but may extend beyond that, and it must include the local area surrounding the Cancer Center.

It must be population-based, e.g., using census tracts, zip codes, county or state lines, or other geographically-defined boundaries. The Six Essential Characteristics of an NCI-Designated Cancer Center A successful NCI-Designated Cancer Center demonstrates strength in six essential characteristics.

Together, these characteristics maximize its scientific potential and produce a whole that is greater than the sum of its parts: Physical Space: Physical facilities dedicated to the conduct of cancer focused research, and to the Center’s Shared Resources, and administration, are appropriate and adequate for the task.

Organizational Capabilities: The Center takes maximum advantage of institutional capabilities in cancer research, engaging in appropriate planning and evaluation of Center strategies and activities. If a consortium is proposed, the consortium institution(s) add significant cancer research expertise to the Center.

Transdisciplinary Collaboration and Coordination: Substantial coordination, interaction, and collaboration, both among Center members from a variety of disciplines and between Center members and investigators in other institutions, enhance and add value to the productivity and quality of research.

As appropriate to the nature of the research, Centers facilitate transition of scientific findings through the translational continuum, via coordination of research across NCI and other funding mechanisms and through collaborations with other partners.

Cancer Focus: The structure and objectives of the Center's Research Programs and other components, as well as, the Center members' grants, contracts, publications, demonstrate a clearly defined cancer research focus. Institutional Commitment: The Center is a formal organizational component of the institution, with sufficient space, positions, and discretionary resources to ensure its stability and fulfill the Center’s objectives.

The Center Director has authorities appropriate for managing the Center and furthering its scientific mission. The institution recognizes team science in its promotion and tenure policies. Center Director: The Director is a highly qualified scientist and administrator with leadership experience and expertise appropriate for establishing a vision for the Center, advancing scientific goals, and managing a complex organization.

She or he is effective in using institutionally designated authorities to manage the Center.

Major Research Areas of Cancer Centers and Types of Interactions An NCI-Designated Cancer Center should feature vigorous interactions across its research areas, facilitating collaboration between basic laboratory; clinical; and prevention, control and population-based science investigators and the formal Research Programs of which they are a part.

The organizational approach should serve the science of the institution, with reasonable breadth and depth of cancer-focused scientific faculty and dedicated research facilities.

In addition, Centers should ensure that they are both fostering basic discovery and, as applicable, facilitating transition of scientific findings through the translational pipeline (i.e., basic to pre-clinical and early clinical development, then to Phase III trials or other types of definitive studies appropriate to the nature of the research).

Discoveries may be advanced through NCI and other peer-reviewed translational science and clinical trial funding mechanisms (e.g. grants for SPOREs, program projects, consortia for Phase 0/I/II Cancer Prevention Clinical Trials Program, and the NCI National Clinical Trials Network or NCTN) and other collaborative strategies, including external partnerships.

All Centers are encouraged to establish collaborative links that maximize productivity and result in appropriate application of findings. The form and extent of these activities may vary, based on the type of Center.

Depending on Center type, the major research areas may include the following: Basic Laboratory Research: Centers use their base of support to promote breadth and depth in basic laboratory research and transdisciplinary collaborations among investigators in basic discovery and other research areas, both within the Center and with other external partners.

Clinical Research: Cancer Centers engage in a broad spectrum of clinical studies with a variety of forms of sponsorship. A Cancer Center is a major source of innovative investigator-initiated clinical studies that can be exported to NCI's NCTN or other appropriate externally peer-reviewed funded mechanisms. Clinical studies involve relevant laboratory research whenever possible.

Cancer Centers foster translation between the laboratory and clinic and conduct early proof-of-principle clinical trials and lead, and/or participate in, NCI’s NCTN. Cancer Centers also participate in trials initiated by industry and other NCI-designated Cancer Centers and other external partners.

Prevention, Control, and Population Science Research: While Cancer Centers may not be able to conduct research in all aspects of prevention, cancer control, and population science, and no one area is required, they demonstrate depth in grant support across several thematic areas (e.g., epidemiology, primary prevention, early detection, health services, dissemination, palliation, and survivorship).

They also demonstrate appropriate collaborative links to other research areas within the Center and with other NCI-Designated Cancer Centers and other external partners. NCI supports the affiliation of independent scientific institutions with distinct scientific expertise with NCI-Designated cancer centers to contribute to the development and actualization of the cancer center's research agenda.

This formalized relationship strengthens the science of the Center and further extends the benefits of its cancer research. Once approved by NCI following peer-review, a consortium partner becomes a formal part of the Cancer Center and may describe themselves as a part of the X NCI-Designated Cancer Center. They may not display the NCI Cancer Center identity badges independently nor describe themselves as NCI-Designated.

Only renewal (Type 2) applications may propose consortium arrangements, which must be fully functioning at the time of application; Type 1 applications may not propose consortium arrangements. A consortium partner with clinical activities must: Hold at least $2.

5 million in direct cost NIH-funded research project grants that are classified as cancer research by NIH’s Research, Condition, and Disease Categorization (RCDC), held by a minimum of 10 PD/PIs. These grants cannot be counted as part of the Center until the consortium arrangement is approved by NCI, following acceptance of the arrangement by the Study Section as part of their overall review of the P30 CCSG application.

Be fully integrated at the level of membership and institutional engagement into the Cancer Center at the time of the CCSG application, as evidenced by a history of collaboration, including joint grants and publications, and mechanisms for including geographically dispersed members in programmatic activities. Common fundraising across the partner institutions is encouraged, but not required.

Subject all clinical protocols to the Cancer Center’s Protocol Review and Monitoring System (PRMS), Data and Safety Monitoring Institutional Plan (DSMP), and Clinical Protocol and Data Management (CPDM). A joint Institutional Review Board (IRB) for evaluation of all cancer research across the partner institutions is encouraged, but not required.

Have participation of the partner’s members in center’s disease- or modality-focused groups, PRMS, and DSMP. Grant the Cancer Center Director some influence in the management of the clinical cancer care program at the consortium partner to ensure that care is aligned with the research mission of the Center.

Have appropriate accrual to clinical trials proportionate to the patient population and clinical research capabilities of the consortium partner. Have an appropriate cancer research administrative structure and staff to support cancer research, member engagement, and participation in Center activities, and that coordinates its efforts with the Center's administration.

Have a formal, written agreement (Memorandum of Understanding) in place to ensure the stability and integration of the consortium partnership.

The agreement should include: A process for resolution of differences at the highest levels of institutional leadership An integrated planning and evaluation process that enables achievement of the Center’s research goals (e.g., identification of future recruitment needs, Shared Resources, Community Outreach and Engagement, and other activities) Ongoing, tangible institutional commitments to the Cancer Center from all consortium partners.

Such commitments should be appropriate to the nature of the consortium and may be demonstrated in a number of ways, including financial and in-kind contributions based on agreed upon formulas, housing and funding of Cancer Center cores, accrual to center-wide trials, active representation and engagement of members in Cancer Center Programs and committees, etc. Full eligibility for membership in formal Research Programs and leadership positions in the Center Reasonable access for all members to Shared Resources and clinical research materials including output from clinical trials, tissues, and HIPAA-compliant patient data Center Director oversight of CCSG-supported Shared Resources, including those located in partner institutions A clear delineation of the Center Director’s influence in the clinical operations at the consortium partner A consortium partner without clinical activity must: Satisfy the requirements listed above, not including clinic-related activities, and hold at least $1.

0 million in direct cost NIH-funded research project grants that are classified as cancer research by NIH’s Research, Condition, and Disease Categorization (RCDC), held by a minimum of 5 PD/PIs.

These grants cannot be counted as part of the Center until the research partnership arrangement is approved by NCI, following acceptance of the arrangement by the NCI’s Cancer Centers Study Section (A) as part of their overall review of the P30 CCSG application. DURATION: The initial budget period will be five years.

In order to enable more long-range planning and pursue high-risk research, Centers may be eligible for an additional two years, for a maximum award period of seven years. Eligibility for the additional years will be based on merit at peer review, sustained exceptional progress, stability, and longevity of the Cancer Center, and contingent upon an administrative review by NCI staff and approval of the National Cancer Advisory Board.

Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs. See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity. Application Types Allowed The OER Glossary and the How to Apply - Application Guide provides details on these application types.

Only those application types listed here are allowed for this NOFO. Optional: Accepting applications that either propose or do not propose clinical trial(s). Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. New (Type 1) applications: Budget should not exceed $1. 2 million (Basic Cancer Center), $1.

4 million (Clinical Cancer Center), $1. 5 million (Comprehensive Cancer Center) in direct costs per year for the project period. Renewal (Type 2) applications: Application budgets are not limited but need to reflect the actual needs of the proposed project.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO. Section III.

Eligibility Information Higher Education Institutions - Includes all types Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized) Eligible Agencies of the Federal Government U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations For New (Type 1) applications , an applicant institution must have a funding base of $10,000,000 (Clinical Cancer Centers) or $6,000,000 (Basic Cancer Centers) in annual direct costs of NIH funding that is cancer-focused, as defined by the Research Condition and Disease Categorization (RCDC) system.

Please contact the NCI Office of Cancer Centers (https://cancercenters. cancer. gov/) for assistance in determining the RCDC funding base.

For Renewal (Type 2) applications , an applicant institution must have a funding base of at least $10,000,000 in annual direct costs of peer-reviewed, cancer-related funding. If the Cancer Center is an approved consortium of institutions, the funding base of the Center will be the sum of the funding bases of all participating institutions.

However, funding (and other data) awarded to consortium partners may be included only if the partner has been previously evaluated in CCSG peer-review and approved by NCI.

Example of NCI peer-reviewed mechanisms that may be included for determining eligibility to apply for a CCSG: DP1, DP2, R00, R01, R03, R15, R18, R21, R24, R25, R33, R35, R37, R41, R42, R50, R55, R56, P01, P20, P30s other than the CCSG, P50, SC1, SC2, U01, U10, U19, U24, U54, U56, UH2, UH3, UG3, T32, K and F series awards and N01s (excluding SEER and other N01s funding materials, services, or research resources).

Cancer-relevant research funded by these mechanisms from other NIH Institutes may also be counted towards the minimum, as do cancer-relevant grants and contracts from the peer-reviewed funding sources listed in: https://cancercenters. cancer. gov/sites/default/files/PeerReviewFundingOrganizations.

pdf NOTE : New (Type 1) applications cannot request evaluation for comprehensiveness status. Foreign Organizations/International Collaborations Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement , are not allowed. Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted.

Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2. 3.

9. 2 Electronically Submitted Applications for additional information. System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually .

The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.

Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM. gov registration process. The same UEI must be used for all registrations, as well as on the grant application.

eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants. gov registration; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.

Grants. gov – Applicants must have an active SAM registration in order to complete the Grants. gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role.

Obtaining an eRA Commons account can take up to 2 weeks. Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply - Application Guide . This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement Section 1. 2- Definitions of Terms.

3. Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time per NIH Grants Policy Statement Section 2.

3. 7. 4 Submission of Resubmission Application .

This means that the NIH will not accept: A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2. 3. 9.

4 Similar, Essentially Identical, or Identical Applications ). Specific to this NOFO: Only one application per institution is allowed, normally identified by having a unique UEI number or NIH IPF number. Section IV.

Application and Submission Information 1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST or an institutional system-to-system solution. A button to apply using ASSIST is available in Part 1 of this NOFO.

See the administrative office for instructions if planning to use an institutional system-to-system solution. 2.

Content and Form of Application Submission It is critical that applicants follow the Multi-Project (M) Instructions in the How to Apply - Application Guide , except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice , or other notice from NIH Guide for Grants and Contracts ) and where instructions in the How to Apply - Application Guide are directly related to the Grants.

gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

All page limitations described in the How to Apply- Application Guide and the Table of Page Limits must be followed.

Component Type for Submission Cancer Center Administration Cancer Research Training & Education Coordination Community Outreach & Engagement Shared Resource Management Leadership Planning & Evaluation Clinical Protocol & Data Management Protocol Review & Monitoring System Instructions for the Submission of Multi-Component Applications The following section supplements the instructions found in How to Apply- Application Guide and should be used for preparing a multi-component application.

The application should consist of the following components: Overall: minimum of 1; maximum of 1 Cancer Center Administration (Admin): minimum of 1; maximum of 1 Cancer Research Training & Education Coordination (CTREC): minimum of 1; maximum of 1 Shared Resource (SR): minimum of 1; no maximum Research Program (Research Prog.) : minimum of 1; no maximum Community Outreach & Engagement (COE Clin. Comp.

Ctr.) : minimum of 1; maximum of 1 for Clinical and Comprehensive Cancer Centers, but not allowed for Basic Cancer Centers Developmental Funds (Dev. Funds): one optional Shared Resource Management (SRM.)

: minimum of 1; maximum of 1 Leadership, Planning & Evaluation (LPE): minimum of 1; maximum of 1 Clinical Protocol & Data Management (CPDM Clin. Comp. Ctr): minimum of 1; maximum of 1 for Clinical and Comprehensive Cancer Centers, but not allowed for Basic Cancer Centers Protocol Review & Monitoring System (PRMS Clin.

Comp. Ctr): minimum of 1; maximum of 1 for Clinical and Comprehensive Cancer Centers, but not allowed for Basic Cancer Centers When preparing the application, use Component Type ‘Overall’. All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions, as noted.

SF424(R&R) Cover (Overall) PHS 398 Cover Page Supplement (Overall) Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component. Research & Related Other Project Information (Overall) Follow standard instructions.

Project/Performance Site Locations (Overall) A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.

Research and Related Senior/Key Person Profile (Overall) Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this NOFO) for the entire application. Facilities and Other Resources: Include a description of the following in a single attachment: 1. Physical Space: A map that illustrates the main location of the